Referred to the House Committee on Energy and Commerce.
The bill directs the Secretary of Commerce to designate a senior official to lead a federal effort to promote U.S. biomanufacturing competitiveness, identify supply-chain vulnerabilities (including reliance on foreign adversaries), and improve transparency of Federal commercialization processes. It requires periodic assessments and reports, a public web resource, voluntary industry practices, interagency consultations (including FDA and EPA points of contact), protections for submitted confidential information, and terminates the program after five years.
Left emphasizes need for funding and labor/environment safeguards.
Relative to its intended legislative type, this bill is a well‑structured administrative/operational measure that establishes roles, timelines, reporting, and interagency coordination to identify biomanufacturing supply‑chain and commercialization vulnerabilities and to improve transparency.
The bill directs the Secretary of Commerce to designate a senior official to lead a federal effort to promote U.S. biomanufacturing competitiveness, identify supply-chain vulnerabilities (including reliance on foreign adversaries), and improve transparency of Federal commercialization processes.
It requires periodic assessments and reports, a public web resource, voluntary industry practices, interagency consultations (including FDA and EPA points of contact), protections for submitted confidential information, and terminates the program after five years.
Narrow, administrative, bipartisan‑friendly approach with modest fiscal impact increases chances, though many such bills stall in committee or need offsets.
Relative to its intended legislative type, this bill is a well‑structured administrative/operational measure that establishes roles, timelines, reporting, and interagency coordination to identify biomanufacturing supply‑chain and commercialization vulnerabilities and to improve transparency.
Left emphasizes need for funding and labor/environment safeguards.
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes need for funding and labor/environment safeguards.
Generally supportive of measures that strengthen domestic production, supply-chain resilience, and reduce reliance on hostile foreign suppliers.
Concerned that the bill contains no direct funding or explicit labor, environmental, or access protections and may lean toward industry-friendly solutions.
Views the bill as a pragmatic, targeted, and administrable approach to mapping barriers and improving coordination for biomanufacturing.
Likes the voluntary, nonprescriptive tone but wants clearer metrics, cost estimates, and follow-through plans.
Cautiously favorable because the bill is largely coordination, information-gathering, and voluntary rather than regulatory, and it focuses on reducing reliance on foreign adversaries.
Wary of long-term expansion of federal bureaucracy and potential industry favoritism.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, administrative, bipartisan‑friendly approach with modest fiscal impact increases chances, though many such bills stall in committee or need offsets.
The bill has not accumulated any surfaced votes yet.
Left emphasizes need for funding and labor/environment safeguards.
Narrow, administrative, bipartisan‑friendly approach with modest fiscal impact increases chances, though many such bills stall in committee…
Relative to its intended legislative type, this bill is a well‑structured administrative/operational measure that establishes roles, timelines, reporting, and interagency coordination to identify biomanufacturing supply…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.